News & Updates
Filter by Specialty:

TAF rivals TDF for CHB suppression after orthotopic liver transplantation
Switching from tenofovir disoproxil fumarate (TDF) regimens to tenofovir alafenamide (TAF) monotherapy demonstrates long-term efficacy and safety in orthotopic liver transplantation (OLT) recipients with chronic hepatitis B virus (HBV) infection, reports a study presented at The Liver Meeting Digital Experience 2021, by the American Association for the Study of Liver Diseases (AASLD 2021).
TAF rivals TDF for CHB suppression after orthotopic liver transplantation
17 Nov 2021
Tenofovir alafenamide safe to use in breastfeeding mothers with CHB
The first human pharmacokinetic study of tenofovir alafenamide (TAF; commercially sold as Vemlidy) monotherapy in breastfeeding women with chronic hepatitis B (CHB) has found low concentrations of TAF and tenofovir in the breastmilk, with negligible exposure to infants.
Tenofovir alafenamide safe to use in breastfeeding mothers with CHB
16 Nov 2021
Double trouble: Alcohol-related liver diseases take a turn for the worse during COVID-19
Higher intake of alcohol and reduced care during the COVID-19 pandemic have triggered a spike in alcohol-related liver diseases, leading to some serious consequences, according to new research.